Europe needs to “catch up” and develop policies and funding streams to support small and medium size enterprises (SMEs) working in the biopharmaceutical sector.
New research published this week argues that dedicated strategies are needed to help emerging companies succeed in the EU. A lack of dedicated EU funding and investment means that SMEs – companies often working at the very cutting edge of medical research – are increasingly looking to more supportive environments outside of Europe.
Analysis from the SME landscape in Europe concurs with President von der Leyen’s commitment in her political guidelines to boost the EU life science sector during the next mandate, and is also supported by the Draghi’s report on competitiveness.
